These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29933728)

  • 1. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
    Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC
    J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
    Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
    Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
    Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
    BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
    Baker M; Cordes L; Brownell I
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases.
    Knackstedt R; Sussman TA; McCahon L; Song JM; Funchain P; Gastman B
    Ann Oncol; 2019 Aug; 30(8):1399-1400. PubMed ID: 31250007
    [No Abstract]   [Full Text] [Related]  

  • 8. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
    Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
    Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab and other recent advances in Merkel cell carcinoma.
    Bommareddy PK; Kaufman HL
    Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
    Barkdull S; Brownell I
    Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma.
    Joseph J; Zobniw C; Davis J; Anderson J; Trinh VA
    Ann Pharmacother; 2018 Sep; 52(9):928-935. PubMed ID: 29616562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab for the treatment of metastatic Merkel cell carcinoma.
    Cordes LM; Gulley JL
    Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
    Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions.
    Gallo M; Guarnotta V; De Cicco F; Rubino M; Faggiano A; Colao A;
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):429-443. PubMed ID: 30617553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.
    Shibayama Y; Kameda H; Ota S; Tsuchida K; Cho KY; Nakamura A; Miyoshi H; Atsumi T
    J Diabetes Investig; 2019 Sep; 10(5):1385-1387. PubMed ID: 30738003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
    Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
    [No Abstract]   [Full Text] [Related]  

  • 19. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall, and disease-specific survival independent of stage at presentation.
    Arron ST; Canavan T; Yu SS
    J Am Acad Dermatol; 2014 Oct; 71(4):684-90. PubMed ID: 24993599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.